Biogen
BIIB
1,060 hedge funds and large institutions have $36.3B invested in Biogen in 2020 Q2 according to their latest regulatory filings, with 96 funds opening new positions, 339 increasing their positions, 438 reducing their positions, and 128 closing their positions.
0.16% less ownership
Funds ownership: 83.33% → 83.17% (-0.16%)
3% less funds holding
Funds holding: 1,098 → 1,060 (-38)
21% less capital invested
Capital invested by funds: $45.8B → $36.3B (-$9.54B)
23% less repeat investments, than reductions
Existing positions increased: 339 | Existing positions reduced: 438
25% less first-time investments, than exits
New positions opened: 96 | Existing positions closed: 128
37% less call options, than puts
Call options by funds: $896M | Put options by funds: $1.43B
57% less funds holding in top 10
Funds holding in top 10: 49 → 21 (-28)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$204M |
| 2 |
Nordea Investment Management
Stockholm,
Sweden
|
+$170M |
| 3 |
JP Morgan Chase
New York
|
+$159M |
| 4 |
D.E. Shaw & Co
New York
|
+$128M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$102M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$925M |
| 2 |
BlackRock
New York
|
-$434M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$409M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$314M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$221M |
BIIB Hedge Fund Activity: Q2 2020 in Review
1,060 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2020, worth a combined $36.3B — down 21% from $45.8B a quarter earlier.
Sellers outnumbered buyers: 128 funds closed out of BIIB and 96 opened new positions — a net loss of 32 holders — while 438 trimmed existing stakes and 339 added.
The largest buyer was Wellington Management Group, adding an estimated $204M. The largest seller was T. Rowe Price Associates, cutting an estimated $925M.
- 1,060 institutional investors held Biogen (BIIB) as of Q2 2020, down from 1,098 in Q1 2020.
- Funds reported $36.3B of Biogen stock for Q2 2020, down 21% quarter-over-quarter.
- 96 funds opened new Biogen positions in Q2 2020 and 128 closed out, a net change of -32 holders.
- The largest Biogen buyer in Q2 2020 was Wellington Management Group, an estimated $204M added.
- The largest Biogen seller in Q2 2020 was T. Rowe Price Associates, an estimated $925M sold.
Based on aggregated 13F filings for Q2 2020.